Maui Derm 2026: Key Insights & Highlights from Dermatology Experts

The February 3, 2026, Maui Derm meeting showcased significant advancements across the field of dermatology, with a particular focus on emerging therapies for inflammatory skin conditions, evolving approaches to oncodermatology, and innovations in pediatric care. The meeting, which brought together leading dermatologists and researchers, highlighted a rapidly evolving era marked by targeted therapies and technological innovation.

Expanding Therapeutic Options for Inflammatory Diseases

A central theme of Maui Derm 2026 was the continued development of treatments for chronic inflammatory and immune-mediated skin conditions. Late-phase data presented at the conference underscored the potential of topical Janus kinase (JAK) inhibitors, specifically ruxolitinib, and Bruton’s tyrosine kinase (BTK) inhibitors as important emerging options. These therapies are demonstrating promise in providing rapid symptom control and more targeted systemic management across a range of inflammatory skin diseases.

Clinical trials involving ruxolitinib cream have shown statistically significant improvements in EASI (Eczema Area and Severity Index) and IGA (Investigator’s Global Assessment) scores by week 8, alongside early reductions in pruritus (itch) in patients 12 years and older. This establishes ruxolitinib as a topical option for achieving short-term symptomatic control with objective skin improvement within two months. Importantly, topical JAK inhibition has demonstrated a favorable safety profile with minimal systemic exposure, even when used in sensitive areas like the scalp and eyelids. Ruxolitinib cream is currently FDA-approved for atopic dermatitis in patients 12 years and older, offering a non-steroidal alternative with rapid itch reduction and improved skin clearance when used as indicated.

Beyond JAK inhibitors, research presented at the meeting also highlighted remibrutinib, which demonstrated rapid reductions in UAS7 (Unpruritic Area Severity Score) with sustained control in chronic spontaneous urticaria. Oral IL-23 receptor blockers and other targeted systemic therapies are emerging as additional options for psoriasis and other difficult-to-treat inflammatory dermatoses, expanding the therapeutic pipeline for refractory disease.

Advances in Oncodermatology

The field of oncodermatology is also evolving, with a shift towards nonsurgical approaches and the increasing use of immune checkpoint inhibitors. These advancements are improving outcomes in aggressive tumors, such as Merkel cell carcinoma.

Precision Care in Pediatric Dermatology

Pediatric dermatology at Maui Derm 2026 emphasized the importance of diagnostic precision and the growing role of systemic therapies. Targeted biologics and JAK inhibitors are transforming care for conditions like atopic dermatitis in children. Roflumilast cream received FDA approval in 2026 for the treatment of mild-to-moderate atopic dermatitis in children aged 2-5, providing a non-steroidal option for this age group.

A Systemic View of Hidradenitis Suppurativa

Hidradenitis suppurativa is increasingly recognized as a systemic inflammatory condition, necessitating a comprehensive care approach that integrates both medical and surgical strategies.

Future Innovations: Photobiomodulation and Bio-Machines

Looking ahead, dermatology is poised for further innovation with the emergence of technologies like photobiomodulation and bio-machines. These advancements promise to extend the reach of dermatological care into the realms of bioengineering and computational science.

Conference Perspectives

Attendees at the February 3, 2026 Maui Derm meeting emphasized its value as a platform for in-depth learning and practical application. One attendee noted the meeting’s ability to allow attendees to “pick and choose what they find to be most important for them and what they want to learn more about,” facilitating a “deep dive” into specific subject matter. Another described Maui Derm as offering “practical pearls” that clinicians can immediately incorporate into their practice, highlighting the quality of the presentations and the valuable networking opportunities.

The collaborative environment fostered at the meeting was also highlighted, with physicians from different specialties – including rheumatology – finding value in co-presenting data and engaging in discussions with dermatologists. This interdisciplinary exchange was described as enriching and valuable.

The meeting’s location in Maui was also acknowledged as a positive aspect, though attendees emphasized that the quality of the scientific content and the opportunity for practical learning were the primary draws.